A Comparative Analysis of MSCs and Their Exosomes in Osteoarthritis Therapy: Complementary Roles and Clinical Translation

AbstractsThere is presently no cure for the degenerative joint disease known as osteoarthritis (OA). Despite the original promise of mesenchymal stem cell (MSC) transplantation, issues such as low cell survival and engraftment have led research to shift toward the exosomes (EXOs) these cells secrete. Because they mirror the immunomodulatory and tissue-regenerative actions of their parent cells without the safety and logistical issues associated with cell-based therapies, MSC-derived EXOs (MSC-EXOs) constitute an emerging class of medicines. For the treatment of OA, this paper offers a comparison and contrast of MSCs and MSC-EXOs. Using data from clinical trials that consistently indicate symptomatic alleviation but provide inconsistent evidence of structural cartilage regeneration, we describe the basic characteristics of MSCs and assess their therapeutic benefits and limitations. The review further examines the pathways by which MSC-EXOs mediate reparative effects on injured joint tissue, highlighting that although preclinical results are encouraging, clinical confirmation is lacking. MSC-EXOs have a less developed body of evidence and greater regulatory uncertainty than MSCs, but they may offer advantages in safety, targeting, and scalability. Standardizing EXO manufacturing and purification procedures, identifying optimal dosage schedules, establishing long-term safety profiles, and engineering EXOs for improved targeting and therapeutic efficacy are important translational issues. In the end, MSC-EXO-based treatment demonstrates potential as a regenerative approach for OA.